Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
64 "Thyroid carcinoma"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Review Articles
Thyroid
Tumor Cells and Cancer-Associated Fibroblasts: A Synergistic Crosstalk to Promote Thyroid Cancer
Laura Fozzatti, Sheue-yann Cheng
Endocrinol Metab. 2020;35(4):673-680.   Published online November 9, 2020
DOI: https://doi.org/10.3803/EnM.2020.401
  • 10,938 View
  • 246 Download
  • 19 Web of Science
  • 18 Crossref
AbstractAbstract PDFPubReader   ePub   
Thyroid cancer is the most common endocrine malignancy. Although most thyroid cancer patients are successfully treated and have an excellent prognosis, a percentage of these patients will develop aggressive disease and, eventually, progress to anaplastic thyroid cancer. Since most patients with this type of aggressive thyroid carcinoma will die from the disease, new treatment strategies are urgently needed. Tumor cells live in a complex and dynamic tumor microenvironment composed of different types of stromal cells. Cancer-associated fibroblasts (CAFs) are one of the most important cell components in the tumor microenvironment of most solid tumors, including thyroid cancer. CAFs originate mainly from mesenchymal cells and resident fibroblasts that are activated and reprogrammed in response to paracrine factors and cytokines produced and released by tumor cells. Upon reprogramming, which is distinguished by the expression of different marker proteins, CAFs synthesize and secret soluble factors. The secretome of CAFs directly impacts different functions of tumor cells. This bi-directional interplay between CAFs and tumor cells within the tumor microenvironment ends up fostering tumor cancer progression. CAFs are therefore key regulators of tumor progression and represent an under-explored therapeutic target in thyroid cancer.

Citations

Citations to this article as recorded by  
  • FAPi-Based Agents in Thyroid Cancer: A New Step towards Diagnosis and Therapy? A Systematic Review of the Literature
    Priscilla Guglielmo, Pierpaolo Alongi, Lucia Baratto, Miriam Conte, Elisabetta Maria Abenavoli, Ambra Buschiazzo, Greta Celesti, Francesco Dondi, Rossella Filice, Joana Gorica, Lorenzo Jonghi-Lavarini, Riccardo Laudicella, Maria Librando, Flavia Linguanti
    Cancers.2024; 16(4): 839.     CrossRef
  • Cancer-associated fibroblasts: protagonists of the tumor microenvironment in gastric cancer
    Ece Ozmen, Tevriz Dilan Demir, Gulnihal Ozcan
    Frontiers in Molecular Biosciences.2024;[Epub]     CrossRef
  • Co-cultivation of human granulosa cells with ovarian cancer cells leads to a significant increase in progesterone production
    Detlef Pietrowski, Martina Grgic, Isabella Haslinger, Julian Marschalek, Christian Schneeberger
    Archives of Gynecology and Obstetrics.2023; 307(5): 1593.     CrossRef
  • Secretome of Stromal Cancer-Associated Fibroblasts (CAFs): Relevance in Cancer
    Deepshikha Mishra, Debabrata Banerjee
    Cells.2023; 12(4): 628.     CrossRef
  • Head-to-Head Comparison of [68Ga]Ga-DOTA.SA.FAPi and [68Ga]Ga-DOTANOC Positron Emission Tomography/Computed Tomography Imaging for the Follow-Up Surveillance of Patients with Medullary Thyroid Cancer
    Sanjana Ballal, Madhav Prasad Yadav, Frank Roesch, Shobhana Raju, Swayamjeet Satapathy, Parvind Sheokand, Euy Sung Moon, Marcel Martin, Shipra Awarwal, Madhavi Tripathi, Chandrasekhar Bal
    Thyroid®.2023; 33(8): 974.     CrossRef
  • Head-to-head comparison of [68Ga]Ga-DOTA.SA.FAPi with [18F]F-FDG PET/CT in radioiodine-resistant follicular-cell derived thyroid cancers
    Sanjana Ballal, Madhav P. Yadav, Frank Roesch, Swayamjeet Satapathy, Euy Sung Moon, Marcel Martin, Nicky Wakade, Parvind Sheokand, Madhavi Tripathi, Kunal R. Chandekar, Shipra Agarwal, Ranjit Kumar Sahoo, Sameer Rastogi, Chandrasekhar Bal
    European Journal of Nuclear Medicine and Molecular Imaging.2023; 51(1): 233.     CrossRef
  • Identifying the cancer-associated fibroblast signature to predict the prognosis and immunotherapy response in patients with lung squamous cell carcinoma
    Yinhui Zhu, Yingqun Zhu, Sirui Chen, Qian Cai
    Computer Methods in Biomechanics and Biomedical Engineering.2023; : 1.     CrossRef
  • Roles and new Insights of Macrophages in the Tumor Microenvironment of Thyroid Cancer
    Qi Liu, Wei Sun, Hao Zhang
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Rab22a Promotes Epithelial-Mesenchymal Transition in Papillary Thyroid Carcinoma by Activating PI3K/AKT/mTOR Signaling Pathway
    Xue Luo, Jinping Wang, Jinxi Lu, Xi Wang, Yuan Miao, Qingchang Li, Xiaoman Li, Liang Wang, Yong Xin Ma
    BioMed Research International.2022; 2022: 1.     CrossRef
  • Extracellular vesicles from thyroid cancer harbor a functional machinery involved in extracellular matrix remodeling
    Rocío del Carmen Bravo-Miana, María Florencia Soler, Danilo Guillermo Ceschin, Félix Royo, Dana María Negretti-Borga, Mikel Azkargorta, Félix Elortza, María del Mar Montesinos, Claudia Gabriela Pellizas, Juan Manuel Falcón-Pérez, Ana Carolina Donadio
    European Journal of Cell Biology.2022; 101(3): 151254.     CrossRef
  • The clinical significance of thyroid hormone-responsive in thyroid carcinoma and its potential regulatory pathway
    Zhen-xing Yu, Cheng Xiang, Sheng-gui Xu, Yang-ping Zhang
    Medicine.2022; 101(31): e29972.     CrossRef
  • Thyroid Cancer and Fibroblasts
    Angelica Avagliano, Giuseppe Fiume, Claudio Bellevicine, Giancarlo Troncone, Alessandro Venuta, Vittoria Acampora, Sabrina De Lella, Maria Rosaria Ruocco, Stefania Masone, Nunzio Velotti, Pietro Carotenuto, Massimo Mallardo, Carmen Caiazza, Stefania Monta
    Cancers.2022; 14(17): 4172.     CrossRef
  • TIM3 Expression in Anaplastic-Thyroid-Cancer-Infiltrating Macrophages: An Emerging Immunotherapeutic Target
    Luz Maria Palacios, Victoria Peyret, María Estefania Viano, Romina Celeste Geysels, Yair Aron Chocobar, Ximena Volpini, Claudia Gabriela Pellizas, Juan Pablo Nicola, Claudia Cristina Motran, María Cecilia Rodriguez-Galan, Laura Fozzatti
    Biology.2022; 11(11): 1609.     CrossRef
  • Recent progress in molecular mechanisms of postoperative recurrence and metastasis of hepatocellular carcinoma
    Zhao-Shan Niu, Wen-Hong Wang, Xiao-Jun Niu
    World Journal of Gastroenterology.2022; 28(46): 6433.     CrossRef
  • Recent advances in regenerative medicine strategies for cancer treatment
    Vahid Mansouri, Nima Beheshtizadeh, Maliheh Gharibshahian, Leila Sabouri, Mohammad Varzandeh, Nima Rezaei
    Biomedicine & Pharmacotherapy.2021; 141: 111875.     CrossRef
  • Secreted Factors by Anaplastic Thyroid Cancer Cells Induce Tumor-Promoting M2-like Macrophage Polarization through a TIM3-Dependent Mechanism
    Cinthia Carolina Stempin, Romina Celeste Geysels, Sunmi Park, Luz Maria Palacios, Ximena Volpini, Claudia Cristina Motran, Eva Virginia Acosta Rodríguez, Juan Pablo Nicola, Sheue-yann Cheng, Claudia Gabriela Pellizas, Laura Fozzatti
    Cancers.2021; 13(19): 4821.     CrossRef
  • Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study
    Sanjana Ballal, Madhav Prasad Yadav, Euy Sung Moon, Frank Roesch, Samta Kumari, Shipra Agarwal, Madhavi Tripathi, Ranjit Kumar Sahoo, Bharadwaj Srinivas Mangu, Avinash Tupalli, Chandrasekhar Bal
    Thyroid.2021;[Epub]     CrossRef
  • Emerging Biomarkers in Thyroid Practice and Research
    Shipra Agarwal, Andrey Bychkov, Chan-Kwon Jung
    Cancers.2021; 14(1): 204.     CrossRef
Close layer
Thyroid
Recent Improvements in Genomic and Transcriptomic Understanding of Anaplastic and Poorly Differentiated Thyroid Cancers
Seong-Keun Yoo, Young Shin Song, Young Joo Park, Jeong-Sun Seo
Endocrinol Metab. 2020;35(1):44-54.   Published online March 19, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.1.44
  • 7,262 View
  • 244 Download
  • 16 Web of Science
  • 18 Crossref
AbstractAbstract PDFPubReader   ePub   

Anaplastic thyroid cancer (ATC) is a lethal human cancer with a 5-year survival rate of less than 10%. Recently, its genomic and transcriptomic characteristics have been extensively elucidated over 5 years owing to advance in high throughput sequencing. These efforts have extended molecular understandings into the progression mechanisms and therapeutic vulnerabilities of aggressive thyroid cancers. In this review, we provide an overview of genomic and transcriptomic alterations in ATC and poorly-differentiated thyroid cancer, which are distinguished from differentiated thyroid cancers. Clinically relevant genomic alterations and deregulated signaling pathways will be able to shed light on more effective prevention and stratified therapeutic interventions for affected patients.

Citations

Citations to this article as recorded by  
  • The genomic and evolutionary landscapes of anaplastic thyroid carcinoma
    Peter Y.F. Zeng, Stephenie D. Prokopec, Stephen Y. Lai, Nicole Pinto, Michelle A. Chan-Seng-Yue, Roderick Clifton-Bligh, Michelle D. Williams, Christopher J. Howlett, Paul Plantinga, Matthew J. Cecchini, Alfred K. Lam, Iram Siddiqui, Jianxin Wang, Ren X.
    Cell Reports.2024; 43(3): 113826.     CrossRef
  • Comparative study between poorly differentiated thyroid cancer and anaplastic thyroid cancer: real-world pathological distribution, death attribution, and prognostic factor estimation
    Kun Zhang, Xinyi Wang, Tao Wei, Zhihui Li, Jingqiang Zhu, Ya-Wen Chen
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer – Real-World Outcomes From UK Centres
    C. Lorimer, L. Cheng, R. Chandler, K. Garcez, V. Gill, K. Graham, W. Grant, S. Sardo Infirri, J. Wadsley, L. Wall, N. Webber, K.H. Wong, K. Newbold
    Clinical Oncology.2023; 35(1): e60.     CrossRef
  • MicroRNA expression profiling of RAS-mutant thyroid tumors with follicular architecture: microRNA signatures to discriminate benign from malignant lesions
    E. Macerola, A. M. Poma, P. Vignali, A. Proietti, L. Torregrossa, C. Ugolini, A. Basolo, A. Matrone, R. Elisei, F. Santini, F. Basolo
    Journal of Endocrinological Investigation.2023; 46(8): 1651.     CrossRef
  • RBX1 regulates PKM alternative splicing to facilitate anaplastic thyroid carcinoma metastasis and aerobic glycolysis by destroying the SMAR1/HDAC6 complex
    Debin Xu, Jichun Yu, Yuting Yang, Yunyan Du, Hongcheng Lu, Shouhua Zhang, Qian Feng, Yi Yu, Liang Hao, Jun Shao, Leifeng Chen
    Cell & Bioscience.2023;[Epub]     CrossRef
  • Multi-Omics and Management of Follicular Carcinoma of the Thyroid
    Thifhelimbilu Emmanuel Luvhengo, Ifongo Bombil, Arian Mokhtari, Maeyane Stephens Moeng, Demetra Demetriou, Claire Sanders, Zodwa Dlamini
    Biomedicines.2023; 11(4): 1217.     CrossRef
  • Genomic landscape of anaplastic thyroid cancer and implications on therapy
    Leslie Cheng, Kate Newbold
    Current Opinion in Endocrine and Metabolic Research.2023; 30: 100458.     CrossRef
  • Modeling the tumor microenvironment of anaplastic thyroid cancer: an orthotopic tumor model in C57BL/6 mice
    Zhen Xu, Hyo Shik Shin, Yoo Hyung Kim, Seong Yun Ha, Jae-Kyung Won, Su-jin Kim, Young Joo Park, Sareh Parangi, Sun Wook Cho, Kyu Eun Lee
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Characterization of the genomic alterations in poorly differentiated thyroid cancer
    Yeeun Lee, SeongRyeol Moon, Jae Yeon Seok, Joon-Hyop Lee, Seungyoon Nam, Yoo Seung Chung
    Scientific Reports.2023;[Epub]     CrossRef
  • Genetica del carcinoma anaplastico della tiroide
    Teresa Ramone, Chiara Mulè, Cristina Romei, Raffaele Ciampi, Eleonora Molinaro, Rossella Elisei
    L'Endocrinologo.2022; 23(2): 208.     CrossRef
  • Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology
    Elena Muraro, Rebecca Romanò, Giuseppe Fanetti, Emanuela Vaccher, Irene Turturici, Valentina Lupato, Fabio Biagio La Torre, Jerry Polesel, Elisabetta Fratta, Vittorio Giacomarra, Giovanni Franchin, Agostino Steffan, Michele Spina, Salvatore Alfieri
    Critical Reviews in Oncology/Hematology.2022; 175: 103707.     CrossRef
  • Recent Improvements in the Treatment of High-Risk Thyroid Cancer
    Eun Kyung Lee
    Korean Society for Head and Neck Oncology.2022; 38(1): 1.     CrossRef
  • Inhibition of Glycogen Metabolism Induces Reactive Oxygen Species-Dependent Cytotoxicity in Anaplastic Thyroid Cancer in Female Mice
    Cole D Davidson, Jennifer A Tomczak, Eyal Amiel, Frances E Carr
    Endocrinology.2022;[Epub]     CrossRef
  • Survival prognostic factors for differentiated thyroid cancer patients with pulmonary metastases: A systematic review and meta-analysis
    Hao Zhao, Chun-Hao Liu, Yue Cao, Li-Yang Zhang, Ya Zhao, Yue-Wu Liu, Hong-Feng Liu, Yan-Song Lin, Xiao-Yi Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
    Keith C. Bible, Electron Kebebew, James Brierley, Juan P. Brito, Maria E. Cabanillas, Thomas J. Clark, Antonio Di Cristofano, Robert Foote, Thomas Giordano, Jan Kasperbauer, Kate Newbold, Yuri E. Nikiforov, Gregory Randolph, M. Sara Rosenthal, Anna M. Saw
    Thyroid.2021; 31(3): 337.     CrossRef
  • Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine
    Antonio Ieni, Roberto Vita, Cristina Pizzimenti, Salvatore Benvenga, Giovanni Tuccari
    Journal of Personalized Medicine.2021; 11(5): 333.     CrossRef
  • The Role of Altered Mitochondrial Metabolism in Thyroid Cancer Development and Mitochondria-Targeted Thyroid Cancer Treatment
    Siarhei A. Dabravolski, Nikita G. Nikiforov, Alexander D. Zhuravlev, Nikolay A. Orekhov, Liudmila M. Mikhaleva, Alexander N. Orekhov
    International Journal of Molecular Sciences.2021; 23(1): 460.     CrossRef
  • Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E
    Young Shin Song, Young Joo Park
    Endocrinology and Metabolism.2020; 35(3): 515.     CrossRef
Close layer
Case Report
A Case of Primary Parathyroid Carcinoma with full-brown Symptom.
Chang Soo Ryu, Deok Ki Kim, Kee Hyun Park, Shi Gyeong Seong, Dong Ho Kim, Sang Min Woo, In Sung Cho
J Korean Endocr Soc. 1996;11(2):221-226.   Published online November 7, 2019
  • 1,304 View
  • 24 Download
AbstractAbstract PDF
Primary hyperparathyroicism is a state of hypersecretion of PTH by the parathyroid. The etiology has not been established. The three possible etiologies of piimary hyperparathyroidism and incidences are adencena(83%), hyperplasia(15%), and carcinoma(1~2%). Parathyroid carcinoma usually presents in the fourth decades. The hallmark preoperative signs are hypercalcemia(serum calcium 15mg/dl). Palpable neck mass and bane and renal disease. Patients may present with multiple signs and syrnptoms, including recurrent nephrolithiasis, peptic ulcers, mental change, less frequently, extensive bone resorption. However, with greater awareness of the disease and wider use of screening tests, including blood calcium determinations, the diagnosis is frequently made in patients who have no symptoms and minimal, if any, signs of the disease ather than hypercalcemia and elevated levels of parathyroid Hormone. An 38-years-old woman was admitted to the hospital due to pain on the left knee joint. We experienced full-brown symptom pertaining to hyperpara- thyroidism. Thus we report a case herein and also discuss clinical anifestation, histologic features and treatment.
Close layer
Original Article
Clinical Significance of Routine Measurement of Serum Calcitonin in Korean Patients with Thyroid Nodules as a Screening test of Sporadic Thyroid Medullary Carcinoma.
Young Kee Shong, Cheol Soo Choi, Hye Young Park, Bo Youn Cho
J Korean Endocr Soc. 1996;11(1):11-17.   Published online November 7, 2019
  • 1,093 View
  • 27 Download
AbstractAbstract PDF
Background
: It is not easy to diagnose sporadic medullary thyroid carcinoma(MTC) before surgery and this might lead the patient reoperation and/or lowered chance of definite cure. Methods : The prevalence of sporadic MTC in Korean was studied in patients with thyroid nodules. A prospective study of 1048 consecutive patients with thyroid nodules was performed. In all patients, measurements of basal serum calcitonin, thyroid hormones, TSH, anti-thyroglobulin antibody and anti-thyroperoxidase antibody were undertaken along with technetium-99m thyroid scintigraphy and fine needle aspiration cytology. In patients with elevated basal calcitonin levels, calcium stimulated calcitonin level was determined. Results: Two patient had markedly elevated calcitonin levels(over 3,200 pg/mL and 1,763 pg/ mL) and another one slightly elevated calcitoni#n(71.9 pg/mL). Fine needle aspiration cytology was suggestive of MTC in one and nodular hyperplasia in the other two. They underwent surgery and histological examination revealed MTC in those two with markedly elevated calcitonin levels. The patient with slightly elevated calcitonin, who was on the maintenance hemodialysis due to chronic renal failure, had nodular hyperplasia. Conclusion: MTC was found in 0.19% of patients with thyroid nodules, which was not different with the previously reported prevalence in Europe. Routine measurements of serum calcitonin might be of value to detect sporadic MTC; however, the cost-effectiveness of routine measurement of serum calcitonin is not clear, considering the relatively low prevalence of MTC in Koreans.
Close layer
Case Report
A Case of Polyglandular Autoimmune Syndrome.
In Pyo Jun, Suck Hwan Lim, Won Hyep Bae, Seung Jun Kim, Youn Ho Lee, Sun Ho Kim, Jung Kyu Lim, Jin Duk Hur
J Korean Endocr Soc. 1994;10(2):142-147.   Published online November 6, 2019
  • 1,164 View
  • 20 Download
AbstractAbstract PDF
Polyglandular autoimmune(PGA) syndrome designates the dysfunction of endocrine and nonendocrine system involving two or more glands on the basis of autoimmunity. There are three types of PGA syndrome and their pathogenesis is still not completely understood. A 27-year-old woman developed polyglandular autoimmune syndrome manifesting insulin-dependent diabetes mellitus, myasthenia gravis and Graves' disease associated papillary thyroid carcinoma. The thyroid antimicrosomal antibody and antiacetylcholine receptor antibody were positive. Her HLA serotype was A2, A11, A62, B60, CW3, CW4, DR4, DR9.We report here a case of polyglandular autoimmune syndrome, type III manifesting insulin-dependent diabetes mellitus, myasthenia gravis and Graves' disease associated with papillary thyroid carcinoma.
Close layer
Original Articles
Thyroid
99mTc-Pertechnetate Scintigraphy Predicts Successful Postoperative Ablation in Differentiated Thyroid Carcinoma Patients Treated with Low Radioiodine Activities
Luca Giovanella, Gaetano Paone, Teresa Ruberto, Luca Ceriani, Pierpaolo Trimboli
Endocrinol Metab. 2019;34(1):63-69.   Published online February 15, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.1.63
  • 4,298 View
  • 66 Download
  • 6 Web of Science
  • 5 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Postoperative routine radioiodine (RAI) treatment is currently debated for patients with low-risk differentiated thyroid carcinoma (DTC) patients. If performed, a low 131I activity (i.e., 1 to 2 GBq) is recommended with the aim to ablate thyroid remnant and facilitate subsequent follow-up by thyroglobulin measurement. The purpose of this study was to evaluate the relationship between postsurgical technetium-99m (99mTc)-pertechnetate scintigraphy and the rate of successful remnant ablation after low activity radioiodine ablation in patients with DTC.

Methods

Enrolled were 193 patients with low risk DTC who underwent total thyroidectomy and RAI ablation with a fixed 1.1 GBq activity of 131I. 99mTc-pertechnetate scans were done and thyrotropin stimulated thyroglobulin (sTg) levels measured just before ablation. Ablation effectiveness was assessed 6 to 12 months later by sTg measurement, neck ultrasound and diagnostic whole body scan.

Results

A negative 99mTc-perthecnetate scans was the best predictor of successful ablation (P<0.001) followed by preablative sTg levels <0.8 ng/mL (P=0.008) and 99mTc-pertechnetate uptake rate values <0.9% (P=0.065). Neither sex nor age of the patient at the time of ablation or tumor histology and size showed a significant association with the rate of successful ablation.

Conclusion

The 99mTc-pertechnetate scintigraphy is a simple and feasible tool to predict effectiveness of low activity 131I thyroid to ablate thyroid remnants in patients with DTC.

Citations

Citations to this article as recorded by  
  • Combined clinical variable and radiomics of post-treatment total body scan for prediction of successful I-131 ablation in low-risk papillary thyroid carcinoma patients
    Maythinee Chantadisai, Jirarot Wongwijitsook, Napat Ritlumlert, Yothin Rakvongthai
    Scientific Reports.2024;[Epub]     CrossRef
  • The prognostic value of post thyroidectomy Tc-99m pertechnetate thyroid scan in patients with differentiated thyroid cancer
    L.M. Eloteify, Samy M. Algizawy, Aya K.M. Abdelnaim, Nesreen Mekkawy
    Nuclear Medicine Communications.2023; 44(1): 38.     CrossRef
  • Correlation analysis of I-131 SPECT/CT uptake parameters with the success ablation treatment of thyroid remnant in patients with low-intermediate-risk differentiated thyroid cancer
    Qian Zhang, Weina Xu
    Nuclear Medicine Communications.2022; 43(10): 1051.     CrossRef
  • Clinical significance of extra-thyroid 99mTc-pertechnetate uptake before initial radioiodine therapy for differentiated thyroid carcinoma
    Bin Long, Li-Fang Yao, Shou-Cong Chen, Jin Shui, Xue-Mei Ye, He-Qing Yi, Cen Lou
    Journal of International Medical Research.2021; 49(5): 030006052110126.     CrossRef
  • Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine
    Antonio Matrone, Alessio Faranda, Francesco Latrofa, Carla Gambale, Delio Stefani Donati, Eleonora Molinaro, Laura Agate, David Viola, Paolo Piaggi, Liborio Torregrossa, Fulvio Basolo, Rossella Elisei
    The Journal of Clinical Endocrinology & Metabolism.2020; 105(8): e2845.     CrossRef
Close layer
Thyroid
Combined Effects of Baicalein and Docetaxel on Apoptosis in 8505c Anaplastic Thyroid Cancer Cells via Downregulation of the ERK and Akt/mTOR Pathways
Chan Ho Park, Se Eun Han, Il Seong Nam-Goong, Young Il Kim, Eun Sook Kim
Endocrinol Metab. 2018;33(1):121-132.   Published online March 21, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.1.121
  • 5,041 View
  • 63 Download
  • 41 Web of Science
  • 35 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background

Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies. Docetaxel, a microtubule stabilizer, is a common chemotherapeutic agent used to treat various metastatic cancers. However, prolonged use results in various side effects and drug resistance. Flavonoids, such as baicalein, are accepted chemotherapeutic and dietary chemopreventive agents with many advantages, such as greater accessibility, affordability, and lower toxicity, compared with traditional chemotherapy agents. In this study, we evaluated whether baicalein enhances the effects of docetaxel on apoptosis and metastasis in 8505c ATC cells.

Methods

The 8505c cells were treated with baicalein or docetaxel individually and in combination. Cell viability was measured by MTT (thiazolyl blue tetrazolium bromide) assay, and apoptosis was detected by fluorescence microscopy of Hoechst-stained cells. The expression of apoptotic (Bax and caspase-3), anti-apoptotic (Bcl-2), angiogenic (vascular endothelial growth factor [VEGF], transforming growth factor β [TGF-β], E-cadherin, and N-cadherin), and signaling (extracellular signal-regulated kinase [ERK] mitogen activated protein kinase [MAPK], Akt, and mammalian target of rapamycin [mTOR]) proteins was determined by Western blot analysis.

Results

The combination of baicalein (50 or 100 µM) and docetaxel (10 nM) significantly inhibited proliferation and induced apoptosis compared with monotherapies. The combination treatment significantly inhibited the expression of Bax, caspase-3, VEGF, TGF-β1, E-cadherin, N-cadherin, and mTOR, but decreased the expression of Bcl-2 and significantly decreased the phosphorylation of ERK and Akt.

Conclusion

The combination of baicalein and docetaxel effectively induced apoptosis and inhibited metastasis in 8505c cells through downregulation of apoptotic and angiogenic protein expression and blocking of the ERK and Akt/mTOR pathways in 8505c cells. These results suggest that baicalein enhances the anticancer effects of docetaxel in ATC.

Citations

Citations to this article as recorded by  
  • Modulation of hypoxia-inducible factor-1 signaling pathways in cancer angiogenesis, invasion, and metastasis by natural compounds: a comprehensive and critical review
    Sajad Fakhri, Seyed Zachariah Moradi, Farahnaz Faraji, Leila Kooshki, Kassidy Webber, Anupam Bishayee
    Cancer and Metastasis Reviews.2024; 43(1): 501.     CrossRef
  • Baicalein Alleviates Arsenic-induced Oxidative Stress through Activation of the Keap1/Nrf2 Signalling Pathway in Normal Human Liver Cells
    Qi Wang, Aihua Zhang
    Current Molecular Medicine.2024; 24(3): 355.     CrossRef
  • Natural products reverse cancer multidrug resistance
    Jia-Yu Zou, Qi-Lei Chen, Xiao-Ci Luo, Davaadagva Damdinjav, Usama Ramadan Abdelmohsen, Hong-Yan Li, Tungalag Battulga, Hu-Biao Chen, Yu-Qing Wang, Jian-Ye Zhang
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Identification of novel characteristic biomarkers and immune infiltration profile for the anaplastic thyroid cancer via machine learning algorithms
    C. Li, X. Dong, Q. Yuan, G. Xu, Z. Di, Y. Yang, J. Hou, L. Zheng, W. Chen, G. Wu
    Journal of Endocrinological Investigation.2023; 46(8): 1633.     CrossRef
  • Promising Role of the Scutellaria baicalensis Root Hydroxyflavone–Baicalein in the Prevention and Treatment of Human Diseases
    Marcelina Chmiel, Monika Stompor-Gorący
    International Journal of Molecular Sciences.2023; 24(5): 4732.     CrossRef
  • STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel
    Sandra M. Rocha, Daniel Nascimento, Rafaella S. Coelho, Ana Margarida Cardoso, Luís A. Passarinha, Sílvia Socorro, Cláudio J. Maia
    International Journal of Molecular Sciences.2023; 24(7): 6643.     CrossRef
  • Baicalein as Promising Anticancer Agent: A Comprehensive Analysis on Molecular Mechanisms and Therapeutic Perspectives
    A K M Helal Morshed, Supti Paul, Arafat Hossain, Tuli Basak, Md. Sanower Hossain, Md. Mehedi Hasan, Md. Al Hasibuzzaman, Tanjim Ishraq Rahaman, Md. Abdur Rashid Mia, Pollob Shing, Md Sohel, Shabana Bibi, Dipta Dey, Partha Biswas, Md. Nazmul Hasan, Long Ch
    Cancers.2023; 15(7): 2128.     CrossRef
  • The role of flavonoids in the regulation of epithelial‐mesenchymal transition in cancer: A review on targeting signaling pathways and metastasis
    Carina Proença, Marisa Freitas, Daniela Ribeiro, Ana T. Rufino, Eduarda Fernandes, José Miguel P. Ferreira de Oliveira
    Medicinal Research Reviews.2023; 43(6): 1878.     CrossRef
  • Developing a ternary conductive hydrogel of polyacrylamide, polyaniline, and carbon nanotube: A potential chemiresistive gas sensor
    Mohsen Peykari, Saeed Pourmahdian
    Journal of Composite Materials.2023; 57(27): 4291.     CrossRef
  • Inhibiting MEK1 R189 citrullination enhances the chemosensitivity of docetaxel to multiple tumour cells
    Teng Xue, Shujia Fei, Jian Gu, Nan Li, Pengxue Zhang, Xiaoqiu Liu, Paul R Thompson, Xuesen Zhang
    Philosophical Transactions of the Royal Society B: Biological Sciences.2023;[Epub]     CrossRef
  • Baicalein improves the chemoresistance of ovarian cancer through regulation of CirSLC7A6
    Shuqing Li, Zhihui Yi, Mingqing Li, Zhiling Zhu
    Journal of Ovarian Research.2023;[Epub]     CrossRef
  • Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin
    Poupak Fallahi, Silvia Martina Ferrari, Giusy Elia, Francesca Ragusa, Armando Patrizio, Sabrina Rosaria Paparo, Gianni Marone, Maria Rosaria Galdiero, Giovanni Guglielmi, Rudy Foddis, Alfonso Cristaudo, Alessandro Antonelli
    Seminars in Cancer Biology.2022; 79: 203.     CrossRef
  • Synergistic effects of BAY606583 on docetaxel in esophageal cancer through modulation of ERK1/2
    Zinab Mohammadi, Jahanbakhsh Asadi, Seyyed Mehdi Jafari
    Cell Biochemistry and Function.2022; 40(6): 569.     CrossRef
  • Regulation of Cell Signaling Pathways and Non-Coding RNAs by Baicalein in Different Cancers
    Ammad Ahmad Farooqi, Gulnara Kapanova, Sundetgali Kalmakhanov, Gulnur Tanbayeva, Kairat S. Zhakipbekov, Venera S. Rakhmetova, Marat K. Syzdykbayev
    International Journal of Molecular Sciences.2022; 23(15): 8377.     CrossRef
  • Crosstalk between xanthine oxidase (XO) inhibiting and cancer chemotherapeutic properties of comestible flavonoids- a comprehensive update
    Md Sohanur Rahaman, Md Afjalus Siraj, Md Arman Islam, Prayas Chakma Shanto, Ordha Islam, Md Amirul Islam, Jesus Simal-Gandara
    The Journal of Nutritional Biochemistry.2022; 110: 109147.     CrossRef
  • Anticancer effects of natural phytochemicals in anaplastic thyroid cancer (Review)
    Yitian Li, Jing Zhang, Huihui Zhou, Zhen Du
    Oncology Reports.2022;[Epub]     CrossRef
  • The Multifaceted Role of Baicalein in Cancer Management through Modulation of Cell Signalling Pathways
    Arshad Husain Rahmani, Ahmad Almatroudi, Amjad Ali Khan, Ali Yousif Babiker, Malak Alanezi, Khaled S. Allemailem
    Molecules.2022; 27(22): 8023.     CrossRef
  • Ouabain Effects on Human Anaplastic Thyroid Carcinoma 8505C Cells
    Mariana Pires Teixeira, Natalia Ferreira Haddad, Eliza Freitas Passos, Marcelle Novaes Andrade, Maria Luisa Arantes Campos, Joyle Moreira Carvalho da Silva, Camila Saggioro de Figueiredo, Elizabeth Giestal-de-Araujo, Denise Pires de Carvalho, Leandro Mira
    Cancers.2022; 14(24): 6168.     CrossRef
  • Baicalein Represses Cervical Cancer Cell Growth, Cell Cycle Progression and Promotes Apoptosis via Blocking AKT/mTOR Pathway by the Regulation of circHIAT1/miR-19a-3p Axis
    Jiaojiao Hu, Runkun Wang, Yi Liu, Jianbo Zhou, Ka Shen, Yun Dai
    OncoTargets and Therapy.2021; Volume 14: 905.     CrossRef
  • Phytochemicals in thyroid cancer: analysis of the preclinical studies
    Stefania Bulotta, Francesca Capriglione, Marilena Celano, Valeria Pecce, Diego Russo, Valentina Maggisano
    Endocrine.2021; 73(1): 8.     CrossRef
  • Cancer-associated fibroblasts (CAFs) in thyroid papillary carcinoma: molecular networks and interactions
    Jeehoon Ham, Bin Wang, Joseph William Po, Amandeep Singh, Navin Niles, Cheok Soon Lee
    Journal of Clinical Pathology.2021; 74(12): 759.     CrossRef
  • Clinical Study of Virtual Reality Augmented Technology Combined with Contrast-Enhanced Ultrasound in the Assessment of Thyroid Cancer
    Qinghua Liu, Jian Cheng, Jingjing Li, Lei Liu, Hongbo Li, Zhihan Lv
    Journal of Healthcare Engineering.2021; 2021: 1.     CrossRef
  • Potential of baicalein in the prevention and treatment of cancer: A scientometric analyses based review
    Elika Verma, Aviral Kumar, Uzini Devi Daimary, Dey Parama, Sosmitha Girisa, Gautam Sethi, Ajaikumar B. Kunnumakkara
    Journal of Functional Foods.2021; 86: 104660.     CrossRef
  • E-cadherin on epithelial–mesenchymal transition in thyroid cancer
    Xiaoyu Zhu, Xiaoping Wang, Yifei Gong, Junlin Deng
    Cancer Cell International.2021;[Epub]     CrossRef
  • Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses
    Gheysen Laetitia, Saussez Sven, Journe Fabrice
    Cells.2020; 9(4): 830.     CrossRef
  • Preclinical and clinical combination therapies in the treatment of anaplastic thyroid cancer
    Daniela Gentile, Paola Orlandi, Marta Banchi, Guido Bocci
    Medical Oncology.2020;[Epub]     CrossRef
  • Interleukin-22 enhances chemoresistance of lung adenocarcinoma cells to paclitaxel
    Zhiliang Huang, Yu Gao, Dianchen Hou
    Human Cell.2020; 33(3): 850.     CrossRef
  • Plant natural products with anti-thyroid cancer activity
    Javad Sharifi-Rad, Sadegh Rajabi, Miquel Martorell, Maria Dolores López, María Trinidad Toro, Susi Barollo, Decio Armanini, Patrick Valere Tsouh Fokou, Giuseppe Zagotto, Giovanni Ribaudo, Raffaele Pezzani
    Fitoterapia.2020; 146: 104640.     CrossRef
  • Baicalein: A metabolite with promising antineoplastic activity
    Hardeep Singh Tuli, Vaishali Aggarwal, Jagjit Kaur, Diwakar Aggarwal, Gaurav Parashar, Nidarshana Chaturvedi Parashar, Muobarak Tuorkey, Ginpreet Kaur, Raj Savla, Katrin Sak, Manoj Kumar
    Life Sciences.2020; 259: 118183.     CrossRef
  • Impact of Antioxidant Natural Compounds on the Thyroid Gland and Implication of the Keap1/Nrf2 Signaling Pathway
    Ana Paunkov, Dionysios V. Chartoumpekis, Panos G. Ziros, Niki Chondrogianni, Thomas W. Kensler, Gerasimos P. Sykiotis
    Current Pharmaceutical Design.2019; 25(16): 1828.     CrossRef
  • Reversal of Multidrug Resistance in Cancer by Multi-Functional Flavonoids
    Qingmei Ye, Kai Liu, Qun Shen, Qingyue Li, Jinghui Hao, Fangxuan Han, Ren-Wang Jiang
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • Inhibition of Cancer Stem-Like Phenotype by Curcumin and Deguelin in CAL-62 Anaplastic Thyroid Cancer Cells
    Mehmet A. Kocdor, Hakan Cengiz, Halil Ates, Hilal Kocdor
    Anti-Cancer Agents in Medicinal Chemistry.2019; 19(15): 1887.     CrossRef
  • Induction of apoptotic but not autophagic cell death by Cinnamomum cassia extracts on human oral cancer cells
    Ching‐Han Yu, Shu‐Chen Chu, Shun‐Fa Yang, Yih‐Shou Hsieh, Chih‐Yi Lee, Pei‐Ni Chen
    Journal of Cellular Physiology.2019; 234(4): 5289.     CrossRef
  • Licochalcone A induces apoptotic cell death via JNK/p38 activation in human nasopharyngeal carcinoma cells
    Chun‐Yi Chuang, Cheng‐Ming Tang, Hsin‐Yu Ho, Chung‐Han Hsin, Chia‐Jui Weng, Shun‐Fa Yang, Pei‐Ni Chen, Chiao‐Wen Lin
    Environmental Toxicology.2019; 34(7): 853.     CrossRef
  • Rab23 contributes to the progression of colorectal cancer via protein kinase B and extracellular signal‑regulated kinase signaling pathways
    Tongbi Zhao, Dong Han, Huan Meng
    Oncology Letters.2019;[Epub]     CrossRef
Close layer
Endocrine Research
Macrophage Densities Correlated with CXC Chemokine Receptor 4 Expression and Related with Poor Survival in Anaplastic Thyroid Cancer
Dae In Kim, Eunyoung Kim, Young A Kim, Sun Wook Cho, Jung Ah Lim, Young Joo Park
Endocrinol Metab. 2016;31(3):469-475.   Published online August 2, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.3.469
  • 4,737 View
  • 52 Download
  • 22 Web of Science
  • 16 Crossref
AbstractAbstract PDFPubReader   
Background

Tumor associated macrophages (TAMs) and CXC chemokine receptor 4 (CXCR4) have emerged as potential biomarkers in various human cancers. The aims of this study were to investigate the clinical characteristics of anaplastic thyroid cancer (ATC) patients according to the TAM numbers in the tumor tissue, and to evaluate the associations between CXCR4 expressions and macrophage densities in ATC tumor microenvironment.

Methods

Total 14 ATC samples from thyroid tissue microarray were used. Immunohistochemical staining was performed using anti-CD163 and anti-CXCR4 antibodies. According to the immunoreactivity of CD163, all subjects were divided into two groups: low-CD163 (n=8) and high-CD163 (n=6) groups.

Results

The mean diagnostic age was 65±7 years and the median tumor size was 4.3 cm, ranging 2.5 to 15 cm. Clinicopathological characteristics were not significantly different between low-CD163 and high-CD163 groups, while age of diagnosis was younger in high-CD163 group than that of low-CD163 group with marginal significance (56.9±5.5 years vs. 67.5±6.8 years, P=0.09). However, overall survival was significantly reduced in high-CD163 group (5.5 months [range, 1 to 10]) compared with low-CD163 groups (8.8 months [range, 6 to 121); log-rank test, P=0.0443). Moreover, high-CD163 group showed strong CXCR4 expressions in both cancer and stromal compartments, while low-CD163 group showed relatively weak, stromal-dominant CXCR4 expressions. Additionally, CD163 and CXCR4 expressions showed a strong positive correlation (γ2=0.432, P=0.013).

Conclusion

Increased number of TAMs showed poor overall survival in ATC, suggesting TAMs are potentially a prognostic biomarker for ATC. CXCR4 expression was significantly correlated with CD163-positive TAM densities, which suggest the possible role of CXCR4 in TAM recruitments.

Citations

Citations to this article as recorded by  
  • IL2RA+VSIG4+ tumor-associated macrophage is a key subpopulation of the immunosuppressive microenvironment in anaplastic thyroid cancer
    Zongfu Pan, Lisha Bao, Xixuan Lu, Xiaoping Hu, Lu Li, Jinming Chen, Tiefeng Jin, Yiwen Zhang, Zhuo Tan, Ping Huang, Minghua Ge
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2023; 1869(1): 166591.     CrossRef
  • Crosstalk between Thyroid Carcinoma and Tumor-Correlated Immune Cells in the Tumor Microenvironment
    Mingyuan Song, Qi Liu, Wei Sun, Hao Zhang
    Cancers.2023; 15(10): 2863.     CrossRef
  • Modeling the tumor microenvironment of anaplastic thyroid cancer: an orthotopic tumor model in C57BL/6 mice
    Zhen Xu, Hyo Shik Shin, Yoo Hyung Kim, Seong Yun Ha, Jae-Kyung Won, Su-jin Kim, Young Joo Park, Sareh Parangi, Sun Wook Cho, Kyu Eun Lee
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Tumor-associated macrophages as a potential therapeutic target in thyroid cancers
    Liya Zhu, Xiu Juan Li, Prakash Gangadaran, Xiuli Jing, Byeong-Cheol Ahn
    Cancer Immunology, Immunotherapy.2023; 72(12): 3895.     CrossRef
  • Functional Phenotypes of Peritoneal Macrophages Upon AMD3100 Treatment During Colitis-Associated Tumorigenesis
    Shuai Wu, Weiwei Luo, Xing Wu, Zhaohua Shen, Xiaoyan Wang
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Integrated analysis of novel macrophage related signature in anaplastic thyroid cancer
    Yi Luo, Yi-Chen Yang, Ben Ma, Wei-Bo Xu, Tian Liao, Yu Wang
    Endocrine.2022; 78(3): 517.     CrossRef
  • Secreted Factors by Anaplastic Thyroid Cancer Cells Induce Tumor-Promoting M2-like Macrophage Polarization through a TIM3-Dependent Mechanism
    Cinthia Carolina Stempin, Romina Celeste Geysels, Sunmi Park, Luz Maria Palacios, Ximena Volpini, Claudia Cristina Motran, Eva Virginia Acosta Rodríguez, Juan Pablo Nicola, Sheue-yann Cheng, Claudia Gabriela Pellizas, Laura Fozzatti
    Cancers.2021; 13(19): 4821.     CrossRef
  • Immunotherapy for anaplastic thyroid carcinoma: the present and future
    Xixuan LU, Lisha BAO, Zongfu PAN, Minghua GE
    Journal of Zhejiang University (Medical Sciences).2021; 50(6): 675.     CrossRef
  • CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy
    Ashraf Mousavi
    Immunology Letters.2020; 217: 91.     CrossRef
  • Nobiletin Alone or in Combination with Cisplatin Decreases the Viability of Anaplastic Thyroid Cancer Cell Lines
    Diana P. Sousa, Marta Pojo, Ana T. Pinto, Valeriano Leite, Ana Teresa Serra, Branca M. Cavaco
    Nutrition and Cancer.2020; 72(2): 352.     CrossRef
  • The Thyroid Tumor Microenvironment: Potential Targets for Therapeutic Intervention and Prognostication
    Laura MacDonald, Jonathan Jenkins, Grace Purvis, Joshua Lee, Aime T. Franco
    Hormones and Cancer.2020; 11(5-6): 205.     CrossRef
  • Mouse Models as a Tool for Understanding Progression in BrafV600E-Driven Thyroid Cancers
    Iñigo Landa, Jeffrey A. Knauf
    Endocrinology and Metabolism.2019; 34(1): 11.     CrossRef
  • Low Lymphocyte-to-Monocyte Ratios Are Associated with Poor Overall Survival in Anaplastic Thyroid Carcinoma Patients
    Jonghwa Ahn, Eyun Song, Hye-Seon Oh, Dong Eun Song, Won Gu Kim, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Min Ji Jeon
    Thyroid.2019; 29(6): 824.     CrossRef
  • Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy
    Christian M. Schürch, Matthias A. Roelli, Stefan Forster, Marie-Hélène Wasmer, Frido Brühl, Renaud S. Maire, Sergio Di Pancrazio, Marc-David Ruepp, Roland Giger, Aurel Perren, Anja M. Schmitt, Philippe Krebs, Roch-Philippe Charles, Matthias S. Dettmer
    Thyroid.2019; 29(7): 979.     CrossRef
  • Recent advances and emerging therapies in anaplastic thyroid carcinoma
    Maria E. Cabanillas, Mark Zafereo, Michelle D. Williams, Renata Ferrarotto, Ramona Dadu, Neil Gross, G. Brandon Gunn, Heath Skinner, Gilbert Cote, Horiana B. Grosu, Priyanka Iyer, Naifa L. Busaidy
    F1000Research.2018; 7: 87.     CrossRef
  • Pathological processes and therapeutic advances in radioiodide refractory thyroid cancer
    Marika H Tesselaar, Johannes W Smit, James Nagarajah, Romana T Netea-Maier, Theo S Plantinga
    Journal of Molecular Endocrinology.2017; 59(4): R141.     CrossRef
Close layer
Endocrine Research
Selective Mitochondrial Uptake of MKT-077 Can Suppress Medullary Thyroid Carcinoma Cell Survival In Vitro and In Vivo
Dmytro Starenki, Jong-In Park
Endocrinol Metab. 2015;30(4):593-603.   Published online December 31, 2015
DOI: https://doi.org/10.3803/EnM.2015.30.4.593
  • 3,913 View
  • 39 Download
  • 16 Web of Science
  • 15 Crossref
AbstractAbstract PDFPubReader   
Background

Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor mainly caused by mutations in the rearranged during transfection (RET) proto-oncogene. Not all patients with progressive MTC respond to current therapy inhibiting RET, demanding additional therapeutic strategies. We recently demonstrated that disrupting mitochondrial metabolism using a mitochondria-targeted agent or by depleting a mitochondrial chaperone effectively suppressed human MTC cells in culture and in mouse xenografts by inducing apoptosis and RET downregulation. These observations led us to hypothesize that mitochondria are potential therapeutic targets for MTC. This study further tests this hypothesis using1-ethyl-2-[[3-ethyl-5-(3-methylbenzothiazolin-2-yliden)]-4-oxothiazolidin-2-ylidenemethyl] pyridinium chloride (MKT-077), a water-soluble rhodocyanine dye analogue, which can selectively accumulate in mitochondria.

Methods

The effects of MKT-077 on cell proliferation, survival, expression of RET and tumor protein 53 (TP53), and mitochondrial activity were determined in the human MTC lines in culture and in mouse xenografts.

Results

MKT-077 induced cell cycle arrest in TT and MZ-CRC-1. Intriguingly, MKT-077 also induced RET downregulation and strong cell death responses in TT cells, but not in MZ-CRC-1 cells. This discrepancy was mainly due to the difference between the capacities of these cell lines to retain MKT-077 in mitochondria. The cytotoxicity of MKT-077 in TT cells was mainly attributed to oxidative stress while being independent of TP53. MKT-077 also effectively suppressed tumor growth of TT xenografts.

Conclusion

MKT-077 can suppress cell survival of certain MTC subtypes by accumulating in mitochondria and interfering with mitochondrial activity although it can also suppress cell proliferation via other mechanisms. These results consistently support the hypothesis that mitochondrial targeting has therapeutic potential for MTC.

Citations

Citations to this article as recorded by  
  • Immunoexpression of HSPA9 and CUL2 in prostatic tissue and adenocarcinoma
    Carlos Gustavo Hirth, Gislane Rocha Vasconcelos, Maria do Perpétuo Socorro Saldanha da Cunha, Carlos Heli Bezerra Leite, Conceição Aparecida Dornelas
    Annals of Diagnostic Pathology.2022; 56: 151843.     CrossRef
  • Analogs of the Heat Shock Protein 70 Inhibitor MKT-077 Suppress Medullary Thyroid Carcinoma Cells
    Seung-Keun Hong, Dmytro Starenki, Oleta T. Johnson, Jason E. Gestwicki, Jong-In Park
    International Journal of Molecular Sciences.2022; 23(3): 1063.     CrossRef
  • Effect of F16-Betulin Conjugate on Mitochondrial Membranes and Its Role in Cell Death Initiation
    Mikhail V. Dubinin, Alena A. Semenova, Darya A. Nedopekina, Eldar V. Davletshin, Anna Yu. Spivak, Konstantin N. Belosludtsev
    Membranes.2021; 11(5): 352.     CrossRef
  • A BAG's life: Every connection matters in cancer
    Elena Mariotto, Giampietro Viola, Carlo Zanon, Sanja Aveic
    Pharmacology & Therapeutics.2020; 209: 107498.     CrossRef
  • Emerging insights into mitochondria-specific targeting and drug delivering strategies: Recent milestones and therapeutic implications
    Sugapriya Dhanasekaran, Divya Venugopal, Noura Al-Dayan, Vijaya Ravinayagam, Arif Ahmed Mohammed
    Saudi Journal of Biological Sciences.2020; 27(12): 3581.     CrossRef
  • Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
    Pui-Kei Wu, Andrew Becker, Jong-In Park
    International Journal of Molecular Sciences.2020; 21(15): 5436.     CrossRef
  • Heat Shock Proteins (HSPs): A Novel Target for Cancer Metastasis Prevention
    Vinayak Narayanankutty , Arunaksharan Narayanankutty, Anusree Nair
    Current Drug Targets.2019; 20(7): 727.     CrossRef
  • Токсичність МАРК у карциномах щитоподібної залози. Механізми пригнічення сигнального каскаду (огляд літератури та власних даних)
    B. B. Guda, V. V. Pushkarev, O. I. Kovzun, V. P. Pushkarev, M. D. Tronko
    Шпитальна хірургія. Журнал імені Л. Я. Ковальчука.2019; (3): 84.     CrossRef
  • Mortalin (GRP75/HSPA9) Promotes Survival and Proliferation of Thyroid Carcinoma Cells
    Dmytro Starenki, Nadiya Sosonkina, Seung-Keun Hong, Ricardo V. Lloyd, Jong-In Park
    International Journal of Molecular Sciences.2019; 20(9): 2069.     CrossRef
  • Mitochondrial autophagosomes as a mechanism of drug resistance in breast carcinoma
    Ayman N. Abunimer, Heba Mohammed, Katherine L. Cook, David R. Soto-Pantoja, Maria Mercedes Campos, Mones S. Abu-Asab
    Ultrastructural Pathology.2018; 42(2): 170.     CrossRef
  • Genotoxic Responses of Mitochondrial Oxygen Consumption Rate and Mitochondrial Semiquinone Radicals in Tumor Cells
    Kumiko Yamamoto, Hironobu Yasui, Tomoki Bo, Tohru Yamamori, Wakako Hiraoka, Toshihide Yamasaki, Ken-ichi Yamada, Osamu Inanami
    Applied Magnetic Resonance.2018; 49(8): 837.     CrossRef
  • Suppression of B-RafV600E melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinone
    Seung-Keun Hong, Dmytro Starenki, Pui-Kei Wu, Jong-In Park
    Cancer Biology & Therapy.2017; 18(2): 106.     CrossRef
  • Mitochondria chaperone GRP75 moonlighting as a cell cycle controller to derail endocytosis provides an opportunity for nanomicrosphere intracellular delivery
    Zhihui Gao, Xiuran Niu, Qing Zhang, Hang Chen, Aiai Gao, Shanshan Qi, Rong Xiang, Mattias Belting, Sihe Zhang
    Oncotarget.2017; 8(35): 58536.     CrossRef
  • Targeted Therapy for Medullary Thyroid Cancer: A Review
    S. R. Priya, Chandra Shekhar Dravid, Raghunadharao Digumarti, Mitali Dandekar
    Frontiers in Oncology.2017;[Epub]     CrossRef
  • Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells
    Dmytro Starenki, Seung-Keun Hong, Pui-Kei Wu, Jong-In Park
    Cancer Biology & Therapy.2017; 18(7): 473.     CrossRef
Close layer
Namgok Lecture 2014
Thyroid
A Closer Look at Papillary Thyroid Carcinoma
Won Bae Kim
Endocrinol Metab. 2015;30(1):1-6.   Published online March 27, 2015
DOI: https://doi.org/10.3803/EnM.2015.30.1.1
  • 4,076 View
  • 36 Download
  • 30 Web of Science
  • 30 Crossref
AbstractAbstract PDFPubReader   

Recent surge of thyroid cancer, especially papillary thyroid carcinoma (PTC), ignited a debate on over-diagnosis of cancer. Such increase in incidence is a worldwide phenomenon, but it has been the most prominent in Korea. Although increased detection might have played a major role, some evidences suggest that true increase in incidence have also contributed to such phenomenon. PTC is a very common disease being the most common cancer in human. As the mortality due to PTC is relatively low, understanding pathophysiology of the disease and risk prediction in individual patient have particular importance for optimal management, but little has been known. I suggest a reason for such a commonality of PTC, and would like to describe my view on some aspects of PTC including unresolved issue on management based on our recent observations.

Citations

Citations to this article as recorded by  
  • Incidence of thyroid cancer in Abu Dhabi, UAE: A registry-based study
    Eiman Alseddeeqi, Ajda Altinoz, Abderrahim Oulhaj, Abubaker Suliman, LuaiA Ahmed
    Journal of Cancer Research and Therapeutics.2023; 19(2): 321.     CrossRef
  • Organochlorine pesticides induce thyroid tumors through oxidative stress; an in vivo and in silico study
    Fouzieh Salimi, Gholamreza Asadikaram, Moslem Abolhassani, Yasin Pourfarjam, Hamid Zeynali Nejad, Mojtaba Abbasi-Jorjandi, Mojgan Sanjari
    Environmental Science and Pollution Research.2023; 30(15): 45046.     CrossRef
  • Appraisal of cytohistomorphology of papillary carcinoma thyroid and its variants with evaluation of discrepant cases
    Supreetha Megalamane, Hemalatha Anatharamiah, CS B. R. Prasad
    Medical Journal of Dr. D.Y. Patil Vidyapeeth.2022;[Epub]     CrossRef
  • Microwave Ablation versus Surgery for Papillary Thyroid Carcinoma: More Therapeutic Options, More Controversies
    Eric vanSonnenberg, Joseph F. Simeone
    Radiology.2022; 304(3): 714.     CrossRef
  • PSHG-TISS: A collection of polarization-resolved second harmonic generation microscopy images of fixed tissues
    Radu Hristu, Stefan G. Stanciu, Adrian Dumitru, Lucian G. Eftimie, Bogdan Paun, Denis E. Tranca, Pavel Gheorghita, Mariana Costache, George A. Stanciu
    Scientific Data.2022;[Epub]     CrossRef
  • Clinical implications of age and excellent response to therapy in patients with high‐risk differentiated thyroid carcinoma
    Meihua Jin, Jonghwa Ahn, Yu‐Mi Lee, Tae‐Yon Sung, Dong Eun Song, Tae Yong Kim, Ki‐Wook Chung, Jin‐Sook Ryu, Won Bae Kim, Young Kee Shong, Min Ji Jeon, Won Gu Kim
    Clinical Endocrinology.2021; 95(6): 882.     CrossRef
  • Level V Lateral Neck Dissection in FNA-proven Papillary Thyroid Carcinoma
    Mohamad S Farahat, Mohamed K Kamel, Doaa A Saad, Hosam M Hamza
    World Journal of Endocrine Surgery.2021; 13(1): 4.     CrossRef
  • SREBP1 as a potential biomarker predicts levothyroxine efficacy of differentiated thyroid cancer
    Cuilin Li, Xiaowei Peng, Jing Lv, Hecun Zou, Jianqiu Liu, Ke Zhang, Zhi Li
    Biomedicine & Pharmacotherapy.2020; 123: 109791.     CrossRef
  • A‐kinase interacting protein 1 as a potential biomarker of advanced tumor features and increased recurrence risk in papillary thyroid carcinoma patients
    Luqing Zhang, Haiying Tao, Kongliang Ke, Cui Ma
    Journal of Clinical Laboratory Analysis.2020;[Epub]     CrossRef
  • A miRNA-clinicopathological nomogram for the prediction of central lymph node metastasis in papillary thyroid carcinoma-analysis from TCGA database
    Mingjun Wang, Rongjing Li, Xiuhe Zou, Tao Wei, Rixiang Gong, Jingqiang Zhu, Zhihui Li
    Medicine.2020; 99(35): e21996.     CrossRef
  • Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy
    Meihua Jin, Jonghwa Ahn, Yu-Mi Lee, Tae-Yon Sung, Won Gu Kim, Tae Yong Kim, Jin-Sook Ryu, Won Bae Kim, Young Kee Shong, Min Ji Jeon
    Endocrinology and Metabolism.2020; 35(3): 602.     CrossRef
  • Ultrasound-Guided Percutaneous Ethanol Ablation for the Management of Recurrent Thyroid Cancer: Evaluation of Efficacy and Impact on Disease Course
    Santiago Tofé, Iñaki Argüelles, Guillermo Serra, Honorato García, Antonia Barcelo, Vicente Pereg
    International Journal of Thyroidology.2020; 13(2): 128.     CrossRef
  • Synergistic repression of thyroid hyperplasia by cyclin C and Pten
    Jan Jezek, Kun Wang, Ruilan Yan, Antonio Di Cristofano, Katrina F. Cooper, Randy Strich
    Journal of Cell Science.2019;[Epub]     CrossRef
  • Relationship between ultrasonographic and pathologic calcification patterns in papillary thyroid cancer
    Bu Kyung Kim, Eun Mi Lee, Jeong Hoon Kim, So Young Oak, Su Kyoung Kwon, Young Sik Choi, Young Ok Kim
    Medicine.2018; 97(41): e12675.     CrossRef
  • Tiam1 promotes thyroid carcinoma metastasis by modulating EMT via Wnt/β-catenin signaling
    Lin Liu, Bo Wu, Haidong Cai, Dan Li, Yushui Ma, Xuchao Zhu, Zhongwei Lv, Youben Fan, Xiaoping Zhang
    Experimental Cell Research.2018; 362(2): 532.     CrossRef
  • Young Age and Male Sex Are Predictors of Large-Volume Central Neck Lymph Node Metastasis in Clinical N0 Papillary Thyroid Microcarcinomas
    Hye-Seon Oh, Suyeon Park, Mijin Kim, Hyemi Kwon, Eyun Song, Tae-Yon Sung, Yu-Mi Lee, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Min Ji Jeon
    Thyroid.2017; 27(10): 1285.     CrossRef
  • Lack of Efficacy of Radioiodine Remnant Ablation for Papillary Thyroid Microcarcinoma: Verification Using Inverse Probability of Treatment Weighting
    Hyemi Kwon, Min Ji Jeon, Won Gu Kim, Suyeon Park, Mijin Kim, Tae Yong Kim, Minkyu Han, Dong Eun Song, Tae-Yon Sung, Jong Ho Yoon, Suck Joon Hong, Jin-Sook Ryu, Young Kee Shong, Won Bae Kim
    Annals of Surgical Oncology.2017; 24(9): 2596.     CrossRef
  • Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer
    Min-Young Lee, Bo Mi Ku, Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Jong-Mu Sun, Se-Hoon Lee, Keunchil Park, Young Lyun Oh, Mineui Hong, Han-Sin Jeong, Young-Ik Son, Chung-Hwan Baek, Myung-Ju Ahn
    Cancer Research and Treatment.2017; 49(4): 906.     CrossRef
  • Long-term outcomes of ethanol injection therapy for locally recurrent papillary thyroid cancer
    Soo Young Kim, Seok-Mo Kim, Hojin Chang, Bup-Woo Kim, Chi Young Lim, Yong Sang Lee, Hang-Seok Chang, Cheong Soo Park
    European Archives of Oto-Rhino-Laryngology.2017; 274(9): 3497.     CrossRef
  • Active Surveillance for Patients With Papillary Thyroid Microcarcinoma: A Single Center’s Experience in Korea
    Hyemi Kwon, Hye-Seon Oh, Mijin Kim, Suyeon Park, Min Ji Jeon, Won Gu Kim, Won Bae Kim, Young Kee Shong, Dong Eun Song, Jung Hwan Baek, Ki-Wook Chung, Tae Yong Kim
    The Journal of Clinical Endocrinology & Metabolism.2017; 102(6): 1917.     CrossRef
  • Preoperative clinicopathological characteristics of patients with solitary encapsulated follicular variants of papillary thyroid carcinomas
    Hyemi Kwon, Min Ji Jeon, Jong Ho Yoon, Suck Joon Hong, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Won Gu Kim, Dong Eun Song
    Journal of Surgical Oncology.2017; 116(6): 746.     CrossRef
  • Does the Risk of Metabolic Syndrome Increase in Thyroid Cancer Survivors?
    Min-Hee Kim, Jin-young Huh, Dong-jun Lim, Moo-Il Kang
    Thyroid.2017; 27(7): 936.     CrossRef
  • Features of papillary thyroid microcarcinoma associated with lateral cervical lymph node metastasis
    Min Ji Jeon, Mi Sun Chung, Hyemi Kwon, Mijin Kim, Suyeon Park, Jung Hwan Baek, Dong Eun Song, Tae‐Yon Sung, Suck Joon Hong, Tae Yong Kim, Won Bae Kim, Young Kee Shong, Jeong Hyun Lee, Won Gu Kim
    Clinical Endocrinology.2017; 86(6): 845.     CrossRef
  • Clinical Analysis of Elderly Thyroid Cancer Patients Following Thyroidect
    Keun Hee Lee, Hak Hoon Jun, Jong Woo Kim, Seung Ki Kim, Jin Hyung Heo
    Korean Journal of Endocrine Surgery.2016; 16(4): 89.     CrossRef
  • Changing trends in the clinicopathological features and clinical outcomes of medullary thyroid carcinoma
    Hyemi Kwon, Won Gu Kim, Tae‐Yon Sung, Min Ji Jeon, Dong Eun Song, Yu‐Mi Lee, Jong Ho Yoon, Ki‐Wook Chung, Suck Joon Hong, Jung Hwan Baek, Jeong Hyun Lee, Tae Yong Kim, Young Kee Shong, Won Bae Kim
    Journal of Surgical Oncology.2016; 113(2): 152.     CrossRef
  • Coexistence of papillary thyroid microcarcinoma and mucosa-associated lymphoid tissue lymphoma in a context of Hashimoto's thyroiditis
    Saul Levy-Blitchtein, Stefany Plasencia-Rebata, Domingo Morales Luna, Juana del Valle Mendoza
    Asian Pacific Journal of Tropical Medicine.2016; 9(8): 812.     CrossRef
  • Clinical Analysis of Elderly Thyroid Cancer Patients Following Thyroidect
    Keun Hee Lee, Hak Hoon Jun, Jong Woo Kim, Seung Ki Kim, Jin Hyung Heo
    Korean Journal of Endocrine Surgery.2016; 16(4): 89.     CrossRef
  • Aberrant Activation of Notch Signaling Inhibits PROX1 Activity to Enhance the Malignant Behavior of Thyroid Cancer Cells
    Dongwon Choi, Swapnika Ramu, Eunkyung Park, Eunson Jung, Sara Yang, Wonhyeuk Jung, Inho Choi, Sunju Lee, Kyu Eui Kim, Young Jin Seong, Mingu Hong, George Daghlian, Daniel Kim, Eugene Shin, Jung In Seo, Vicken Khatchadourian, Mengchen Zou, Wei Li, Roger De
    Cancer Research.2016; 76(3): 582.     CrossRef
  • Metformin-Associated Lactic Acidosis
    Sunghwan Suh
    Endocrinology and Metabolism.2015; 30(1): 45.     CrossRef
  • Administration of Radioactive Iodine Therapy Within 1 Year After Total Thyroidectomy Does Not Affect Vocal Function
    Chang Hwan Ryu, Junsun Ryu, Youn Mi Ryu, You Jin Lee, Eun-Kyung Lee, Seok-Ki Kim, Tae-Sung Kim, Tae Hyun Kim, Chang Yoon Lee, Seog Yun Park, Ki Wook Chung, Yuh-S. Jung
    Journal of Nuclear Medicine.2015; 56(10): 1480.     CrossRef
Close layer
Case Report
Thyroid
Medullary Thyroid Carcinoma with Ectopic Adrenocorticotropic Hormone Syndrome
Hong Seok Choi, Min Joo Kim, Chae Ho Moon, Jong Ho Yoon, Ha Ra Ku, Geon Wook Kang, Im Il Na, Seung-Sook Lee, Byung-Chul Lee, Young Joo Park, Hong Il Kim, Yun Hyi Ku
Endocrinol Metab. 2014;29(1):96-100.   Published online March 14, 2014
DOI: https://doi.org/10.3803/EnM.2014.29.1.96
  • 3,713 View
  • 40 Download
  • 4 Web of Science
  • 4 Crossref
AbstractAbstract PDFPubReader   

Ectopic adrenocorticotropic hormone (ACTH) syndrome is caused most frequently by a bronchial carcinoid tumor or by small cell lung cancer. Medullary thyroid carcinoma (MTC) is a rare etiology of ectopic ACTH syndrome. We describe a case of Cushing syndrome due to ectopic ACTH production from MTC in a 48-year-old male. He was diagnosed with MTC 14 years ago and underwent total thyroidectomy, cervical lymph node dissection and a series of metastasectomies. MTC was confirmed by the pathological examination of the thyroid and metastatic mediastinal lymph node tissues. Two years after his last surgery, he developed Cushingoid features, such as moon face and central obesity, accompanied by uncontrolled hypertension and new-onset diabetes. The laboratory results were compatible with ectopic ACTH syndrome. A bilateral adrenalectomy improved the clinical and laboratory findings that were associated with Cushing syndrome. This is the first confirmed case of ectopic ACTH syndrome caused by MTC in Korea.

Citations

Citations to this article as recorded by  
  • Medullary Thyroid Cancer with Ectopic Cushing's Syndrome: A Case Report and Systematic Review of Detailed Cases from the Literature
    Andrea Corsello, Vittoria Ramunno, Pietro Locantore, Giovanni Pacini, Esther Diana Rossi, Francesco Torino, Alfredo Pontecorvi, Carmela De Crea, Rosa Maria Paragliola, Marco Raffaelli, Salvatore Maria Corsello
    Thyroid.2022; 32(11): 1281.     CrossRef
  • Mucosal Neuroma Cues for Endocrine Emergency Treatment
    Gyu Gang Choi, Hwan Jin Lee, Hyo Jin Han, Young Beom Jeong, Heung Bum Lee, Ji Hyun Park
    Endocrinology and Metabolism.2021; 36(6): 1312.     CrossRef
  • Articles in 'Endocrinology and Metabolism' in 2014
    Won-Young Lee
    Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
  • Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome
    Fabián Pitoia, Fernanda Bueno, Angélica Schmidt, Sabrina Lucas, Graciela Cross
    Archives of Endocrinology and Metabolism.2015; 59(4): 343.     CrossRef
Close layer
Original Article
Predictive Factors for Incidental Contralateral Carcinoma in Patients with Unilateral Micropapillary Thyroid Carcinoma.
Jung Eun Huh, Sang Soo Kim, Ji Hyun Kang, Bo Gwang Choi, Byung Joo Lee, Jin Choon Lee, Yun Kyung Jeon, Bo Hyun Kim, Soo Geun Wang, Yong Ki Kim, In Joo Kim
Endocrinol Metab. 2012;27(3):194-199.   Published online September 19, 2012
DOI: https://doi.org/10.3803/EnM.2012.27.3.194
  • 54,240 View
  • 21 Download
  • 1 Crossref
AbstractAbstract PDF
BACKGROUND
Whether thyroid lobectomy alone is a sufficient treatment for papillary thyroid microcarcinoma (PTMC) remains controversial. The aim of this study is to evaluate the predictive factors for incidental contralateral carcinoma in patients confirmed of unilateral PTMC preoperatively. METHODS: Between January 2007 and December 2009, 393 patients underwent thyroid surgery for unifocal and unilateral PTMC preoperatively at Pusan National University Hospital. A total thyroidectomy with central neck dissection was routinely performed for these patients during this study period. RESULTS: Among the 393 cases in the cohort, 77 patients (19.6%) had incidental PTMC in the contralateral lobe. In patients with incidental contralateral carcinoma, there was higher prevalence in extrathyroid extension, occult ipsilateral carcinoma, pathologic Hashimoto's thyroiditis, and central lymph node metastasis compared to those without contralateral carcinoma. The mean tumor size also increased in patients with contralateral carcinoma. Multivariate logistic regression showed that extrathyroid extension (P = 0.049), occult ipsilateral carcinoma (P < 0.001), pathologic Hashimoto's thyroiditis (P = 0.038), and central lymph node metastasis (P = 0.002) were predictive factors for incidental contralateral carcinoma. CONCLUSION: In conclusion, multifocality in the ipsilateral lobe, central lymph node metastasis, extrathyroid extension, and Hashimoto's thyroiditis is associated with the presence of contralateral carcinoma. Thus, if these factors are found by preoperative and/or postoperative evaluation, total thyroidectomy or completion thyroidectomy is necessary for the treatment of PTMC.

Citations

Citations to this article as recorded by  
  • Extent of surgery did not affect recurrence during 7‐years follow‐up in papillary thyroid cancer sized 1‐4 cm: Preliminary results
    Min Joo Kim, Myung‐Chul Lee, Guk Haeng Lee, Hoon Sung Choi, Sun Wook Cho, Su‐jin Kim, Kyu Eun Lee, Young Joo Park, Do Joon Park
    Clinical Endocrinology.2017; 87(1): 80.     CrossRef
Close layer
Case Reports
Four Cases of Malignant Pleural Effusion in Patients with Papillary Thyroid Carcinoma.
Min Ji Jeon, Ji Hye Yim, Eui Young Kim, Won Gu Kim, Tae Yong Kim, Won Bae Kim, Young Kee Shong
Endocrinol Metab. 2011;26(4):330-334.   Published online December 1, 2011
DOI: https://doi.org/10.3803/EnM.2011.26.4.330
  • 40,492 View
  • 30 Download
  • 3 Crossref
AbstractAbstract PDF
Papillary thyroid carcinoma could be a rare cause of malignant pleural effusion. The development of malignant pleural effusion in patients with papillary thyroid cancer is an extremely adverse prognostic indicator. Here, we report four cases that showed development of malignant pleural effusion during the clinical course of the papillary thyroid carcinoma and consider the prognosis. In four patients, the median survival time after the development of malignant pleural effusion was only 17 months.

Citations

Citations to this article as recorded by  
  • Pleural fluid due to papillary thyroid cancer
    Tomohiro Tamura, Toshihiro Shiozawa, Hiroaki Satoh, Koichi Kurishima, Katsunori Kagohashi, Norio Takayashiki, Nobuyuki Hizawa
    Oncology Letters.2019;[Epub]     CrossRef
  • Outcome and characteristics of patients with malignant pleural effusion from differentiated thyroid carcinoma
    Chisato Tomoda, Yuna Ogimi, Fumi Saito, Chie Masaki, Junko Akaishi, Kenichi Matsuzu, Akifumi Suzuki, Takashi Uruno, Keiko Ohkuwa, Hiroshi Shibuya, Wataru Kitagawa, Mitsuji Nagahama, Kiminori Sugino, Koichi Ito
    Endocrine Journal.2016; 63(3): 257.     CrossRef
  • A distinctive colour associated with high iodine content in malignant pleural effusion from metastatic papillary thyroid cancer: a case report
    Andrew Rosenstengel, Ee Mun Lim, Michael Millward, YC Gary Lee
    Journal of Medical Case Reports.2013;[Epub]     CrossRef
Close layer
A Case of Subacute Thyroiditis Associated with Papillary Thyroid Carcinoma and Takayasu's Arteritis.
Dongwon Yi, Seung Hoon Baek, Seok Man Son, Yang Ho Kang
Endocrinol Metab. 2011;26(4):324-329.   Published online December 1, 2011
DOI: https://doi.org/10.3803/EnM.2011.26.4.324
  • 1,907 View
  • 24 Download
AbstractAbstract PDF
Subacute thyroiditis is a self-limiting inflammation of the thyroid, presenting with painful thyroid swelling, thyrotoxicosis and low radioactive iodine uptake. The characteristic US findings for this disease are focal ill-defined hypoechoic areas in one lobe or diffuse hypoechoic areas in both lobes. Thyroid carcinomas should be included in the differential diagnosis for a lesion with focal hypoechoic areas and have been rarely reported to coexist with subacute thyroiditis. Takayasu's arteritis is an autoimmune disease that affects the aorta and its branches as well as pulmonary arteries. Subacute thyroiditis associated with Takayasu's arteritis is extremely rare, with only three cases being reported. We report here on the first case with the simultaneous diagnosis of subacute thyroiditis, papillary thyroid carcinoma and Takayasu's arteritis.
Close layer
Original Article
Association between Serum Thyroid Stimulating Hormone Level and Papillary Thyroid Microcarcinoma in Korean Euthyroid Patients.
Hyun Sook Kim, Seung Joon Lee, Jung Kyu Park, Chang Ho Jo, Ho Sang Shon, Eui Dal Jung
Endocrinol Metab. 2011;26(4):297-302.   Published online December 1, 2011
DOI: https://doi.org/10.3803/EnM.2011.26.4.297
  • 1,927 View
  • 26 Download
  • 1 Crossref
AbstractAbstract PDF
BACKGROUND
Thyroid cancer is a common disease and its prevalence is increasing. Recent reports have shown that an elevated thyrotropin (thyroid stimulating hormone, TSH) level is associated with thyroid cancer risk. However, the association between TSH level and thyroid cancer risk is not yet known for euthyroid patients diagnosed with papillary thyroid microcarcinoma (PTMC). METHODS: Our study included 425 patients who underwent thyroid surgery and were diagnosed with PTMC between 2008 and 2009. Control group patients were diagnosed with benign nodules < or = 1 cm in size by US-guided fine needle aspiration. Nodules with one or more suspected malignant-ultrasonographic feature(s) were excluded from this study. Patients who were not euthyroid or who took thyroid medication were also excluded. RESULTS: The mean age of all patients was 48.5 +/- 11.0 years and 88.8% were women. The mean age of those with PTMC was significantly lower than that of the control group. The mean TSH level was 1.78 +/- 0.93 mIU/L, and the mean free T4 level was 15.96 +/- 2.32 pmol/L. There was no difference in TSH level between the PTMC and control groups (1.77 +/- 0.93 mIU/L vs. 1.79 +/- 0.91 mIU/L, P = 0.829). After adjusting for age, TSH level was not correlated with tumor size (r = 0.02, P = 0.678) in the PTMC group. Moreover, the TSH level did not differ between patients with stage I and stage III-IV carcinoma (stage I, 1.77 +/- 0.95 mIU/L; stage III-IV, 1.79 +/- 0.87 mIU/L; P = 0.856). CONCLUSION: TSH levels are not elevated in euthyroid PTMC patients. Thus, further evaluation is needed before serum TSH can be used as a tumor marker for small nodules < or = 1 cm in size in euthyroid patients.

Citations

Citations to this article as recorded by  
  • Evaluation of serum thyroid‐stimulating hormone as indicator for fine‐needle aspiration in patients with thyroid nodules
    Ji Soo Choi, Chung Mo Nam, Eun‐Kyung Kim, Hee Jung Moon, Kyung Hwa Han, Jin Young Kwak
    Head & Neck.2015; 37(4): 498.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism